REGENXBIO Inc.·4

Feb 3, 4:46 PM ET

PAKOLA STEVE 4

Research Summary

AI-generated summary

Updated

REGENXBIO (RGNX) CMO Steve Pakola Withholds 5,267 Shares for Taxes

What Happened
Steve Pakola, Chief Medical Officer of REGENXBIO (RGNX), had 5,267 shares of common stock withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. The withholding was calculated at $11.16 per share, representing a total value of $58,780, and reported on Form 4 for the Feb 1, 2026 vesting.

Key Details

  • Transaction date and price: Feb 1, 2026; shares withheld at $11.16 per share.
  • Shares involved: 5,267 shares withheld (disposition code F — tax withholding).
  • Shares owned after transaction: Not specified in this filing.
  • Footnote: Withholding relates to RSUs granted Aug 1, 2024; number withheld was based on the Feb 1, 2026 closing price.
  • Filing timeliness: Form 4 was filed Feb 3, 2026, which appears timely (within the standard two-business-day reporting window).

Context
This was a tax-withholding event tied to RSU vesting (disposition code F), not an open-market sale. Such withholdings are routine administrative transactions to cover tax liabilities and do not by themselves indicate a change in insider sentiment about the company. The transaction reduced the number of issued shares held by Pakola but was not a cash sale.